8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
US traded shares of AC Immune were up more than 9% at $2.56 in pre-market activity today, as the Swiss biotech said its ACI-24.060 anti-amyloid beta (Abeta) vaccine for Alzheimer's disease (AD) showed positive initial interim safety and immunogenicity in a Phase Ib/II trial dubbed ABATE. 26 January 2023
After a career that has seen him lead Exelixis, Biogen and most recently, Vir Biotechnology, George Scangos is to retire in early April. 26 January 2023
An interview reflecting on 2022 and looking forward to the year ahead with Paul O'Donohoe senior director, eCOA Product and Science at Medidata. 26 January 2023
As global macroeconomic uncertainty hit fundraising across all sectors, investment in UK biotechnology fell from the all-time highs seen in 2021, a new analysis from the industry lobby group UK BioIndustry Association (BIA) and data and insights company Clarivate shows. 26 January 2023
Pharma industry analyst GlobalData has highlighted the strength of data supporting a submission from US biotech Intercept Pharmaceuticals in non-alcoholic steatohepatitis (NASH). 26 January 2023
On December 23 2022, the FDA Modernization Act 2.0 was passed with full support from both the US House of Representatives and the Senate.1 This act aims to improve the process for approving drugs and commits to significantly reducing the use of dogs, primates, and other animals in laboratory testing. 26 January 2023
Shares of US retinal eye disorder specialist Ocuphire Pharma slumped more than 29% to $2.66, after it released disappointing top-line efficacy and safety results from its ZETA-1 Phase II trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR). 26 January 2023
Already expected to reach blockbuster status with its 2022 sales, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has won another approval in Europe. 26 January 2023
In the second setback in the space of a little over a month, Magenta Therapeutics saw its shares crash 23.3% to $0.38 pre-market today, after the US biotech revealed that the latest participant dosed at the Cohort 3 level (0.08mg/kg) in the ongoing MGTA-117 Phase I/II dose-escalation clinical trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 serious adverse event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117. 26 January 2023
The UK’s health technology assessor has approved the first chimeric antigen receptor (CAR) T-cell therapy for use on the National Health Service (NHS) in England. 26 January 2023
KSQ Therapeutics, a privately-held US biotech developing therapies to treat cancer and autoimmune diseases using its CRISPRomics platform, has announced a deal with Ono Pharmaceutical. 25 January 2023
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee has voted favorably, by 14 to 1, that Cidara Therapeutics, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin. 25 January 2023
US drugmaker Eli Lilly is to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility in North Carolina. 25 January 2023
Histiocytic neoplasms, also known as histiocytosis, are rare disorders in which specialized immune cells (histiocytes) accumulate and form tumors in tissues such as skin, bones, liver, lungs, lymph nodes and spleen.1,2 25 January 2023
The Chinese Center for Disease Control and Prevention has recorded that Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in the country. 25 January 2023
The European Medicines Agency is to review a regulatory submission from Swiss gene editing specialist CRISPR Therapeutics and partner Vertex Pharmaceutical. 25 January 2023
The US Department of Health and Human Services (HHS) yesterday issued a new report showing the major savings coming to people with Medicare thanks to the $35 cap on a month’s supply of insulin. 25 January 2023
Deciphera Pharmaceuticals’ shares rose 4.4% to $18.85 in after-hours trading yesterday, when the US biopharma company presented additional data from the planned exploratory analysis from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. 25 January 2023
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.